Exelixis, Inc. (NASDAQ:EXEL) Shares Bought by Meeder Asset Management Inc.

Meeder Asset Management Inc. boosted its stake in Exelixis, Inc. (NASDAQ:EXEL) by 26.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,957 shares of the biotechnology company’s stock after buying an additional 2,091 shares during the period. Meeder Asset Management Inc.’s holdings in Exelixis were worth $245,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the company. Creative Planning increased its position in Exelixis by 82.1% in the second quarter. Creative Planning now owns 92,538 shares of the biotechnology company’s stock valued at $2,279,000 after buying an additional 41,730 shares during the last quarter. Handelsinvest Investeringsforvaltning increased its position in Exelixis by 55.4% in the second quarter. Handelsinvest Investeringsforvaltning now owns 98,500 shares of the biotechnology company’s stock valued at $2,426,000 after buying an additional 35,100 shares during the last quarter. Capstone Asset Management Co. acquired a new position in Exelixis during the second quarter valued at $242,000. Point72 Asset Management L.P. acquired a new position in Exelixis during the first quarter valued at $2,167,000. Finally, Credit Suisse AG increased its position in Exelixis by 20.1% in the first quarter. Credit Suisse AG now owns 768,110 shares of the biotechnology company’s stock valued at $16,646,000 after buying an additional 128,398 shares during the last quarter. 79.93% of the stock is owned by institutional investors.

Exelixis, Inc. (NASDAQ EXEL) traded down 2.05% during mid-day trading on Friday, reaching $26.33. The company’s stock had a trading volume of 2,497,407 shares. The firm’s 50 day moving average price is $26.43 and its 200 day moving average price is $22.52. The stock has a market cap of $7.74 billion, a price-to-earnings ratio of 132.98 and a beta of 1.89. Exelixis, Inc. has a 12-month low of $10.04 and a 12-month high of $28.45.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.06 EPS for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.02. The business had revenue of $99.01 million during the quarter, compared to the consensus estimate of $85.27 million. Exelixis had a return on equity of 80.43% and a net margin of 18.20%. The business’s revenue for the quarter was up 173.1% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.15) earnings per share. On average, equities analysts predict that Exelixis, Inc. will post $0.26 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was first posted by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/meeder-asset-management-inc-purchases-2091-shares-of-exelixis-inc-nasdaqexel-updated-updated-updated.html.

EXEL has been the subject of several recent analyst reports. Oppenheimer Holdings, Inc. restated a “market perform” rating on shares of Exelixis in a research note on Friday, April 21st. Zacks Investment Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. TheStreet upgraded Exelixis from a “d” rating to a “c+” rating in a research report on Tuesday, May 2nd. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Friday, June 16th. Finally, BidaskClub upgraded Exelixis from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Five research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Exelixis presently has a consensus rating of “Buy” and an average price target of $25.57.

In other news, insider Patrick J. Haley sold 5,000 shares of Exelixis stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $18.46, for a total value of $92,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.10% of the stock is owned by insiders.

Exelixis Company Profile

Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.

Institutional Ownership by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply